Featured in NEJM Journal Watch: Updated Guidelines for HER2 Testing in Breast Cancer — Physician’s First Watch
Featured in NEJM Journal Watch: Updated Guidelines for HER2 Testing in Breast Cancer
By the NEJM Journal Watch Editors
The guidelines carry recommendations for oncologists and pathologists. In NEJM Journal Watch, oncologist William Gradishar comments: "The availability of more human epidermal growth factor receptor 2-targeted therapies for breast cancer makes it imperative that HER2 testing is optimally performed and interpreted to give patients the best therapy options."